[Evaluation of the crystal inhibitory effect of angiotensin II type I receptor blocker in etylene glycol treated rat kidney].
OBJECTIVE
We examined whether there would be any inhibitive effect to the crystal formation in ethylene glycol treated rat kidney by angiotensin II type I receptor blocker (candesartan).


METHODS
We divided 10-weeks-old male Sprague-Dawley rats into 4 groups. In these groups, rats were given tap water (group A), 1.0% ethylene glycol (group B), 1.0% ethylene glycol and 20 microg/ml candesartan (group C), 20 microg/ml candesartan (group D) for 4 weeks. Immunohistochemical studies of a renal tissue was performed by ED1 antibody and the osteopontin antibody, the transcription of renin, angiotensin converting enzyme, angiotensin II and osteopontin mRNA in whole kidney was determined using real time PCR and malondialdehyde level was measured. Renal tissue was evaluated using H.E. stain for counting the calcium deposit in the renal tubules. Calcium concentrations in whole kidney were measured with an atomic absorption spectrophotometer.


RESULTS
Although there is no significant difference urinary oxalate and calcium levels compared with group B and C, group C showed fewer the numbers of calcium deposit in the tubules and decreased the amount of calcium contained in the whole kidney, ED1 positive cells, osteopontine mRNA expression and malondialdehyde level.


CONCLUSIONS
These results suggest that candesartan inhibited superfluously induced osteopontin in the whole kidney by ethylene glycol and crystal formation was also related decreased.
Hatanaka
Yuji
Y
Department of Urology, Kinki University School of Medicine.
Umekawa
Tohru
T
Iguchi
Masanori
M
Kurita
Takashi
T
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D000818:Animals; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D002129:Calcium Oxalate / Q000378:metabolism; D003460:Crystallization; D019855:Ethylene Glycol / Q000737:chemistry; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013777:Tetrazoles
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; D002129:Calcium Oxalate; D019855:Ethylene Glycol; C081643:candesartan